LATHAM & WATKINS LLP
JD, Georgetown University, 1993
AB, Columbia University, 1990
Mr. Aslani-Far is admitted to practice in New York.
Areas of Expertise
M. Adel Aslani-Far is a partner in the New York office of Latham & Watkins and Global Co-Chair of the Firm’s Mergers & Acquisitions Practice. Mr. Aslani-Far’s practice focuses on representing large multinational corporations in negotiated and hostile public M&A transactions and a broad range of private acquisitions and joint ventures around the world. He has substantial experience advising special committees of boards of directors and regularly counsels clients on corporate governance and takeover defense matters.
Chambers and Partners has recognized Mr. Aslani-Far as a leading US M&A lawyer for six consecutive years, noting that clients say he is "a strong negotiator" and "particularly effective when the other side is being especially difficult" yet "business-minded and affable" and "creative in trying to solve problems." Mr. Aslani-Far was selected by The New York Times in 2007 as one of the leading dealmakers on Wall Street under the age of 40. He currently serves as a member of the Committee on Mergers, Acquisitions and Corporate Control Contests of the Association of the Bar of the City of New York.
Eli Lilly and Company in numerous acquisitions, including those of ImClone Systems, ICOS Corp., Alnara Pharmaceuticals, an EC-mandated divestiture of Pfizer/Wyeth animal health products,
Johnson & Johnson's animal health business, Monsanto Company's animal health business and an equity investment in United Therapeutics Corp.
Qatar Investment Authority in its strategic alliance with NYSE Euronext to develop an integrated cash and derivatives exchange in Qatar.
GTCR Golder Rauner, LLC in its cash tender offer acquisition of Protection One, Inc.
Thoratec Corporation in the proposed sale of its International Technidyne subsidiary to Danaher.
Ratos AB of Sweden in the sale of two US operating subsidiaries to 3D Systems Corporation.
In addition, he advises the major investment banking firms, including Bank of America Merrill Lynch, Barclays Capital, Credit Suisse, Goldman Sachs and JP Morgan, in numerous transactions in their capacity as financial advisors.